477781-63-8

Upstream product

• 77-76-9 2,2-dimethoxy-propane 
• 477781-62-7 (3R,4S,5R,6R)-5-(benzyloxy)-4,6-dimethylheptane-1,3,7-triol 
• 760978-01-6 endo-3-benzyloxy-endo,endo-2,4-dimethyl-8-oxabicyclo-[3.2.1]-octan-6-one 
• 238757-51-2 (1S,5R,6S,7S,8S)-7-Benzyloxy-6,8-dimethyl-2,9-dioxa-bicyclo[3.3.1]nonan-3-one 
• 171231-72-4 endo-3-benzyloxy-endo,endo-2,4-dimethyl-exo-6-hydroxy-8-oxabicyclo[3.2.1]octane 
• 96691-92-8 (1R,2R,3r,4S,5S)-3-(benzyloxy)-2,4-dimethyl-8-oxa-bicyclo[3.2.1]oct-6-ene 

Downstream Products

• 147659-07-2 (+)-prelactone B 
• 760977-99-9 (3R,4S,5R)-5-Benzyloxy-3-hydroxy-4,6-dimethyl-heptanal 
• 1403660-66-1 (2R,3R,4S,5R)-3-(benzyloxy)-7-(tert-butyldimethylsilyloxy)-5-hydroxy-2,4-dimethylheptyl pivalate 
• 1403660-75-2 (2R,3R,4S,5R)-3-(benzyloxy)-5,7-dihydroxy-2,4-dimethylheptyl pivalate 
• 1403660-73-0 ethyl 2-((R,4E,6E)-N-(2,4-dimethoxybenzyl)-6-methyl-3-oxo-8-((1R,3R,4S,5R)-1,4,8-tri-methyl-2,9-dioxabicyclo[3.3.1]non-7-en-3-yl)nona-4,6-dienamido)acetate 
• 1403660-65-0 (2R,3R,4S)-3-(benzyloxy)-4-((R)-2,2-dimethyl-1,3-dioxan-4-yl)-2-methylpentyl pivalate 
• 956223-76-0 C₃₃H₄₄O₄Si 
• 956223-75-9 C₂₈H₄₂O₃Si 
• 956223-74-8 C₂₈H₄₂O₄Si 
• 956223-83-9 C₂₄H₃₅N₃O₄ 
• 956223-82-8 C₄₄H₇₃N₃O₅Si₂ 
• 956223-85-1 C₃₅H₄₉N₃O₅ 
• 956223-80-6 C₅₄H₇₆O₆Si₂ 
• 956223-79-3 C₄₇H₆₈O₆Si₂ 

Relevant academic research and scientific papers

Total synthesis of (?)-tirandamycin c utilizing a desymmetrization protocol

A highly stereoselective total synthesis of (?)-tirandamycin C has been achieved following a desymmetrization protocol developed in our group, Horner-Wadsworth-Emmons olefination, acid-catalyzed ketalization, Still-Gennari (Z)-selective olefination, and D

An efficient synthesis of (+)-prelactone B

An enantioselective synthesis of (+)-prelactone B 1 has been achieved on a multigram scale starting from a known bicyclic precursor 2. The key feature of the strategy is the generation of 3-stereogenic centres from a single bicyclic precursor, which has b

A stereoconvergent synthesis of the C(19)-C(31) fragment of scytophycin C

The C(19)-C(31) fragment of the anti-tumor macrolide, scytophycin C, was realized in a stereoconvergent manner utilizing a desymmetrization approach to create eight contiguous asymmetric centers from a common precursor.